Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(22):1659; doi:10.1093/jnci/94.22.1659
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 22, 1659, November 20, 2002
© 2002 Oxford University Press

Press Release

Imatinib Shows Early Promise Against Ewing’s Sarcoma

Linda Wang, Assistant News Editor, Katherine Arnold, News Editor

jncimedia@oupjournals.org

The first 10% of the full text of this article appears below.

Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing’s sarcoma, a bone tumor in children and adolescents. In a study in the November 20 issue of the Journal of the National Cancer Institute, treatment with imatinib induced cell death in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?